INOZYME PHARMA INC's ticker is INZY and the CUSIP is 45790W108. A total of 40 filers reported holding INOZYME PHARMA INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $5,602,000 | -56.4% | 2,090,436 | -22.5% | 0.11% | -57.7% |
| Q2 2022 | $12,862,000 | +34.1% | 2,696,372 | +15.0% | 0.26% | +23.8% |
| Q1 2022 | $9,590,000 | -40.0% | 2,344,786 | 0.0% | 0.21% | -36.1% |
| Q4 2021 | $15,991,000 | -41.2% | 2,344,786 | 0.0% | 0.34% | -36.8% |
| Q3 2021 | $27,176,000 | -26.8% | 2,344,786 | +7.6% | 0.53% | -19.7% |
| Q2 2021 | $37,130,000 | -4.5% | 2,178,985 | +10.9% | 0.66% | -19.2% |
| Q1 2021 | $38,887,000 | +63.8% | 1,964,000 | +70.7% | 0.82% | +74.2% |
| Q4 2020 | $23,742,000 | -21.5% | 1,150,299 | 0.0% | 0.47% | -36.3% |
| Q3 2020 | $30,241,000 | – | 1,150,299 | – | 0.74% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Pivotal bioVenture Partners Investment Advisor LLC | 1,591,154 | $18,441,000 | 6.52% |
| CHI Advisors LLC | 920,264 | $10,666,000 | 3.11% |
| Sofinnova Investments, Inc. | 2,028,308 | $23,508,000 | 1.39% |
| MPM BioImpact LLC | 320,724 | $3,717,000 | 0.58% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,344,786 | $27,176,000 | 0.53% |
| NEA Management Company, LLC | 2,444,379 | $28,330,000 | 0.34% |
| Rock Springs Capital Management LP | 850,015 | $9,852,000 | 0.21% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 986,400 | $11,432,000 | 0.19% |
| Overbrook Management Corp | 16,726 | $194,000 | 0.04% |
| Orbimed Advisors | 294,000 | $3,407,000 | 0.04% |